Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on Biomarkers
International Journal of Molecular Sciences · 31.01.2025 · 26 (3) · 1235
DOI: 10.3390/ijms26031235 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 31.01.2025. Verfasst von Areti Strati und 5 weiteren Autor:innen. Beteiligte Einrichtung: Analysis of Circulating Tumor Cells, Lab of Analytical Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, 15771 Athe…. Hauptthemen laut MEDLINE: Neoplasms, Programmed Cell Death 1 Receptor, B7-H1 Antigen, Biomarkers, Tumor. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 174 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The PD1/PD-L1 axis plays an important immunosuppressive role during the T-cell-mediated immune response, which is essential for the physiological homeostasis of the immune system. The biology of the immunological microenvironment is extremely complex and crucial for the development of treatment strategies for immunotherapy. Characterization of the immunological, genomic or transcriptomic landscape of cancer patients could allow discrimination between responders and non-responders to anti-PD-1/PD-L1 therapy. Immune checkpoint inhibitor (ICI) therapy has shown remarkable efficacy in a variety of malignancies in landmark trials and has fundamentally changed cancer therapy. Current research focuses on strategies to maximize patient selection for therapy, clarify mechanisms of resistance, improve existing biomarkers, including PD-L1 expression and tumor mutational burden (TMB), and discover new biomarkers. In this review, we focus on the function of the PD-1/PD-L1 signaling pathway and discuss the immunological, genomic, epigenetic and transcriptomic landscape in cancer patients receiving anti-PD-1/PD-L1 therapy. Finally, we provide an overview of the clinical trials testing the efficacy of antibodies against PD-1/PD-L1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Analysis of Circulating Tumor Cells, Lab of Analytical Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, 15771 Athens, Greece.
- Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
- Department of Medical Oncology, Second Department of Internal Medicine, Attikon University General Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece.
ORCID-Profile: Areti Strati, Christos Adamopoulos, Evi Lianidou, Athanasios G Papavassiliou
Zitieren
APA
Strati, A., Adamopoulos, C., Kotsantis, I., Psyrri, A., Lianidou, E., & Papavassiliou, A. G. (2025). Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on Biomarkers. International Journal of Molecular Sciences, 26(3), 1235. https://doi.org/10.3390/ijms26031235
Vancouver
Strati A, Adamopoulos C, Kotsantis I, Psyrri A, Lianidou E, Papavassiliou AG. Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on Biomarkers. International Journal of Molecular Sciences. 2025;26(3):1235. doi:10.3390/ijms26031235
BibTeX
@article{Strati2025,
author = {Strati, Areti and Adamopoulos, Christos and Kotsantis, Ioannis and Psyrri, Amanda and Lianidou, Evi and Papavassiliou, Athanasios G},
title = {Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on Biomarkers},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {3},
pages = {1235},
doi = {10.3390/ijms26031235}
}
EUVIMED